Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median effective dose of esketamine combined with remimazolam for painless adult day-case hysteroscopic surgery
ChiCTR2200057106Phase 4Not yet recruiting
- Sponsor
- Hainan General Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine and remimazolam in None (2 arms), sponsored by Hainan General Hospital. Primary endpoints: Median effective dose and 95% confidence limits. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
esketamineremimazolam
Beyond the preview
Go deeper on ChiCTR2200057106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057106.